Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KETOHCA: Esketamine for Neuroprotection in OHCA
NCT06744361Phase 2Recruiting
- Start
- Dec 2024
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of esketamine in hypoxic ischemic brain injury (HIBI). Started Dec 2024; status: recruiting.
02
Drugs
esketamine
03
Conditions
hypoxic ischemic brain injury (HIBI)
Beyond the preview
Go deeper on NCT06744361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06744361.